国际眼科杂志
國際眼科雜誌
국제안과잡지
International Eye Science
2015年
10期
1720-1722
,共3页
鼠神经生长因子%复发樟柳碱%非动脉炎性前部缺血性视神经病变%视野
鼠神經生長因子%複髮樟柳堿%非動脈炎性前部缺血性視神經病變%視野
서신경생장인자%복발장류감%비동맥염성전부결혈성시신경병변%시야
mouse nerve growth factor%compound anisodine%nonarteritic anterior ischemic optic neuropathy%visual field
目的：评价鼠神经生长因子联合复方樟柳碱对非动脉炎性前部缺血性视神经病变( nonarteritic anterior ischemic optic neuropathy, NAION)的疗效。<br> 方法：采用临床病例系列研究,将122例单眼发病NAION患者分为3组,所有患者均接受常规治疗。对照组A (40例40眼)给予复方樟柳碱注射液2 mL/次颞浅动脉旁皮下注射,2次/d；对照组 B (41例41眼)鼠神经生长因子30μg/次肌肉注射,1次/d；联合组(41例41眼)同时给予复方樟柳碱和鼠神经生长因子治疗,连续治疗4 wk。每天观察视力、眼底,治疗结束后检查记录最佳矫正视力( BCVA)、视野、OCT,对结果进行统计分析。<br> 结果：联合组视力、视野恢复优于两对照组,差异有统计学意义(P<0.05),视神经纤维层变薄联合组少于两对照组,差异有统计学意义(P<0.05)；两对照组视力、视野、视神经纤维层变化均无统计学差异(P>0.05)。对照组A治疗有效率为70%,对照组B有效率为65.9%,联合组有效率为92.7%,联合组有效率显著高于两对照组,差异有统计学意义(P<0.05)；两对照组间总体治疗效果无统计学差异(P>0.05)。<br> 结论：鼠神经生长因子联合复发樟柳碱可显著提高NAION治疗效果。
目的：評價鼠神經生長因子聯閤複方樟柳堿對非動脈炎性前部缺血性視神經病變( nonarteritic anterior ischemic optic neuropathy, NAION)的療效。<br> 方法：採用臨床病例繫列研究,將122例單眼髮病NAION患者分為3組,所有患者均接受常規治療。對照組A (40例40眼)給予複方樟柳堿註射液2 mL/次顳淺動脈徬皮下註射,2次/d；對照組 B (41例41眼)鼠神經生長因子30μg/次肌肉註射,1次/d；聯閤組(41例41眼)同時給予複方樟柳堿和鼠神經生長因子治療,連續治療4 wk。每天觀察視力、眼底,治療結束後檢查記錄最佳矯正視力( BCVA)、視野、OCT,對結果進行統計分析。<br> 結果：聯閤組視力、視野恢複優于兩對照組,差異有統計學意義(P<0.05),視神經纖維層變薄聯閤組少于兩對照組,差異有統計學意義(P<0.05)；兩對照組視力、視野、視神經纖維層變化均無統計學差異(P>0.05)。對照組A治療有效率為70%,對照組B有效率為65.9%,聯閤組有效率為92.7%,聯閤組有效率顯著高于兩對照組,差異有統計學意義(P<0.05)；兩對照組間總體治療效果無統計學差異(P>0.05)。<br> 結論：鼠神經生長因子聯閤複髮樟柳堿可顯著提高NAION治療效果。
목적：평개서신경생장인자연합복방장류감대비동맥염성전부결혈성시신경병변( nonarteritic anterior ischemic optic neuropathy, NAION)적료효。<br> 방법：채용림상병례계렬연구,장122례단안발병NAION환자분위3조,소유환자균접수상규치료。대조조A (40례40안)급여복방장류감주사액2 mL/차섭천동맥방피하주사,2차/d；대조조 B (41례41안)서신경생장인자30μg/차기육주사,1차/d；연합조(41례41안)동시급여복방장류감화서신경생장인자치료,련속치료4 wk。매천관찰시력、안저,치료결속후검사기록최가교정시력( BCVA)、시야、OCT,대결과진행통계분석。<br> 결과：연합조시력、시야회복우우량대조조,차이유통계학의의(P<0.05),시신경섬유층변박연합조소우량대조조,차이유통계학의의(P<0.05)；량대조조시력、시야、시신경섬유층변화균무통계학차이(P>0.05)。대조조A치료유효솔위70%,대조조B유효솔위65.9%,연합조유효솔위92.7%,연합조유효솔현저고우량대조조,차이유통계학의의(P<0.05)；량대조조간총체치료효과무통계학차이(P>0.05)。<br> 결론：서신경생장인자연합복발장류감가현저제고NAION치료효과。
AIM:To evaluate the clinical efficacy of mouse nerve growth factor combined with compound anisodine on the treatment of nonarteritic anterior ischemic optic neuropathy ( NAION) . <br> METHODS:Clinical case series study was applied. One hundred and twenty-two patients with monocular onset NAION were randomly divided into three groups. Routine treatment was given to all of patients. Control group A ( 40 patients with 40 eyes ) were undergone subcutaneous injection of compound anisodine besides superficial temporal artery, 2mL each time, twice per day; control group B ( 41 patients with 41 eyes ) were given intramuscular injection of mouse nerve growth factor, 30μg each time, once per day;and the combined group ( 41 patients with 41 eyes ) received compound anisodine and mouse nerve growth factor for four consecutive weeks. Visual acuity and fundus were observed every day during the treatment period. When the treatment finished, the best corrected visual acuity ( BCVA ) , visual field and OCT were checked and recorded. The results were analyzed. <br> RESULTS:The recovery of visual acuity and visual field in the combined group was better than those of two control groups (P<0. 05). Optic nerve fiber layer became thinner in the combined group which was still thicker than that in the control groups after the treatment , and there was significantly statistical difference (P<0. 05). Visual acuity, visual field and retinal nerve fiber layer had no statistical differences between control group A and control group B (P>0. 05). The effective rates of the three groups were respectively 70% ( control group A ) , 65. 9% (control group B), 92. 7% (the combined group). The overall effective rate of patients in the combined group was significantly higher than that of two control groups ( P< 0. 05 ), while the clinical efficacy of two control groups had no statistical difference (P>0. 05). <br> CONCLUSION: Mouse nerve growth factor combined with compound anisodine has a remarkable effect on the treatment of NAION.
